GlassScriptPhysician profile
Sami Nizam
NPI 1205150190
$8,809.88
in general payments reported to CMS, 2019-2025
9 companies · $266 in 2025
The $266 reported for 2025 was more than what a typical Oral & Maxillofacial Surgery provider received nationally (typical 2025 total: $184).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,352 · 2020: $444 · 2021: $156 · 2022: $304 · 2023: $192 · 2024: $1,096 · 2025: $266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $850 · Food and Beverage: $654 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $850.24 |
| Food and Beverage | $654.07 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $5,325.07 | 2019-2025 | |
| Nobel Biocare USA | $1,456.09 | 2019-2023 | Nobelactive |
| Abbvie INC. | $1,106.16 | 2023-2025 | |
| Galderma Laboratories, L.P. | $279.97 | 2019-2025 | |
| Revance Therapeutics, INC. | $220.33 | 2024-2025 | Daxxify |
| Stryker Corporation | $178.30 | 2019 | |
| Zimvie INC. | $125.00 | 2022-2024 | |
| Allergan, INC. | $106.37 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $12.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sami Nizam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.